Hematology 2023 (2 Hours)

Author: Anderson Continuing Education
Publisher: Anderson Continuing Education
Date Published: 2023
Pages: 14
Cover Type: Soft Cover
Expiration Date: 12/31/2025



The participant will:


  • Identify the key to successful hemostasis.
  • Compare coagulation models.
  • List phases of the cell-based model of coagulation.
  • Name the coagulation factor that forms D-dimers and other fibrin degradation products.

Normal Hemostasis

  • Specify what initiates the coagulation process.
  • Identify the possible coagulation factors that may be involved when certain PT and aPTT results are found.
  • Match the TEG and ROTEM parameters with their corresponding descriptions.

Investigation of Abnormal Hemostasis

  • List laboratory findings typical of patients with hemophilia A.
  • Indicate why recombinant preparations are preferred for the treatment of hemophilia A.
  • State the role of antifibrinolytics in the treatment of hemophilia A.
  • Characterize hemophilia B.
  • Identify the use for the Nijmegen-modified Bethesda inhibitor assay.
  • List the three most important screening assays for von Willebrand disease (vWD).
  • Name the vWD variant that causes a severe hemophilia-like disease.

Inherited Hemostatic Defects

  • Specify the cause of disseminated intravascular coagulation (DIC).
  • Distinguish between overt and non-overt DIC.
  • Identify the main triggering mechanism of DIC.
  • Describe the most important aspect of managing patients with DIC.
  • Name the disorder associated with the “lethal triad.”
  • Specify the laboratory test usually used to guide perioperative or periprocedural plasma therapy.
  • Identify the reason for most hemostatic defects found in uremic patients.
  • Identify how excessive coagulation with warfarin is managed.
  • Name the substance/condition monitored by the ecarin clotting time chromogenic assay.

Acquired Hemostatic Defects



This course meets the Florida one-hour specialty requirement in hematology.

For those certified by ASCP, this course provides two contact hours in hematology.

The purpose of this activity is to promote the improvement of health care through the provision of continuing education to clinical laboratory personnel. These goals will be accomplished by:

  • Review of the procoagulant and anticoagulant activities that maintain normal hemostasis in the healthy individual and discussion of conditions that lead to disruption of hemostasis and result in bleeding or clotting disorders.
  • Discussion of laboratory testing in the investigation of abnormal hemostasis.
  • Presentation of the most common inherited, and acquired hemostatic disorders, including description of defects found in these conditions, expected laboratory results, physical and physiological findings, and treatment or management of these conditions.
“Inherited and acquired Disorders of Haemostasis,” by Irina Chibisov, Jansen Seheult and Franklin Bontempo. Chapter 28 of Practical Transfusion Medicine, Sixth Edition, pages 337-350. Edited by Michael F. Murphy, David J. Roberts, Mark H. Yazer and Nancy M. Dunbar. Published 2022 by John Wiley & Sons Ltd

NameDeliveryCourse CodeHoursPrice 
Reading Material and QuizShipped2HEMA232.0$15.00
Reading Material and QuizOnline2HEMA23 (Online)2.0$15.00
Name / Course CodePrice / DeliveryHours 
Reading Material and Quiz
Reading Material and Quiz
(2HEMA23 (Online))